Diagnostic Workup for Suspected CIDP

Critical Imaging and Laboratory Tests

The American College of Neurology recommends ruling out compressive lesions that can mimic CIDP, and neoplastic causes, particularly important given that 47% of motor CIDP patients have associated inflammatory, infectious, or neoplastic conditions, with MRI of the entire spine with and without contrast 1
Elevated CSF protein with normal or mildly elevated white blood cells is the classic finding in CIDP, though elevated WBCs can occur in immune checkpoint inhibitor-related cases, according to the Journal of Clinical Oncology 1
Comprehensive serum testing should include vitamin B12 and folate levels, thyroid function (TSH), HIV testing, and consideration of vasculitic and autoimmune screening panel, as recommended by the Journal of Clinical Oncology 2

In cases of acute-onset presentation, serum antiganglioside antibody tests for Guillain-Barré syndrome subtypes should be considered, as suggested by the Journal of Clinical Oncology 1
If associated with immune checkpoint inhibitor therapy, troponin to evaluate myocardial involvement, ECG and echocardiogram if respiratory insufficiency or elevated CPK, and consideration of paraneoplastic autoantibody testing are recommended, according to the Journal of Clinical Oncology 1 and 2

Early neurology consultation is recommended, particularly for grade 2 or higher symptoms, to guide electrodiagnostic interpretation and help differentiate CIDP from mimickers like amyloidosis, vasculitic neuropathy, or paraneoplastic syndromes, as suggested by the Journal of Clinical Oncology 1

The American Academy of Neurology recommends that symptoms evolving over at least 8 weeks distinguish CIDP from Guillain-Barré syndrome 3

Electrodiagnostic studies, including nerve conduction studies and EMG, are mandatory for diagnosis, according to the American Academy of Neurology 4, 5
MRI spine with and without contrast is essential for evaluating nerve root enhancement and thickening, and for ruling out compressive lesions and neoplastic causes, as recommended by the American College of Radiology 4, 5
CSF analysis should include cell count with differential, protein, glucose, cytology, and gram stain, with elevated protein being typical of CIDP, often >45 mg/dL, as noted by the American Academy of Neurology 4, 5
Comprehensive serum testing should screen for reversible causes and CIDP mimickers, including diabetes, vitamin deficiencies, and autoimmune disorders, as recommended by the American Association of Clinical Endocrinologists 4, 5

The presence of symptoms progressing over more than 8 weeks, treatment-related fluctuations, and acute-onset CIDP diagnosed if ≥3 relapses or progression ≥8 weeks after onset, are key differentiators from Guillain-Barré syndrome, as noted by the European Academy of Neurology 3
Nerve biopsy can confirm demyelination with onion bulb formation and inflammatory infiltrates, but is not routinely required if clinical, electrodiagnostic, and CSF findings are consistent, as stated by the American Academy of Physical Medicine and Rehabilitation 6

Blood glucose testing is essential to exclude diabetes in patients with suspected CIDP 7
Serum protein immunofixation electrophoresis is critical to detect monoclonal gammopathies in patients with suspected CIDP 7